Origin Therapeutics Portfolio Company Posts Strong 2021 Following Successful Miami Conference

Microdose Psychedelic Insights’ Wonderland: Miami conference was the largest in-person conference in the psychedelic medicine business

Vancouver, B.C.January 202022 Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce that its portfolio company, Microdose Psychedelic Insights (“Microdose”), has completed a strong 2021, topping it off with an industry-leading, star-studded conference in Miami.

Microdose is a psychedelic industry-focused media company that delivers content, financial analysis, events, and educational material to drive the psychedelics industry forward. Its Q4 revenue hit $1.4 million (CAD), which increased its year one guidance more than 23% to $3.7 million, putting it on track for profitability by Q3 of 2022.

“Microdose has established itself as a leading media and content powerhouse in the emerging psychedelics industry,” said Origin Therapeutics CEO, Alexander Somjen. “The Miami conference was a monumental success, despite the ongoing pandemic, and this has put Microdose not only on the map, but placed it firmly as a leader in the sector in the collective mind of the industry.”

More than 1,600 people attended multiple days of live programming featuring 139 speakers, and 55 sponsors. The event’s presence on social media was palpable in Miami and beyond, generating 25.7 million impressions, reaching roughly 5.7 million people, and generating 2,600 mentions.

The conference included numerous leading psychedelic medical experts, investors, indigienous leaders, and medicine people, as well as several celebrity advocates including Mike Tyson and Lamar Odom.

Microdose Psychedelic Insights is hosting its next event, Psychedelic Capital, on Thursday January 27, 2022 at 1:30 p.m. EST.  The speakers will provide updates on the top companies, IPOS, and newest opportunities in the psychedelic industry. Get tickets: https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-jan-2022/

Origin Therapeutics is focused on identifying and investing in private, early-stage companies in the psychedelics industry, to provide its investors with diversified exposure to this nascent and groundbreaking industry.

Subscribe to updates about Origin Therapeutics online at: https://originpsychedelics.com/


About Origin Therapeutics

Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify leading and emerging global companies for its portfolio that are innovating in the sector and are supported by science. Learn more: https://originpsychedelics.com/


For Further Information:

Alexander Somjen
Chief Executive Officer and Director
Origin Therapeutics Holdings Inc

For media inquiries, please contact: Brittany@Exvera.com

Forward-Looking Information and Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.